1. 00070 A MULTICENTRE PHASE II TRIAL OF GEFITINIB 500 MG/ DAY IN PATIENTS WITH RECURRENT EGFR-POSITIVE GYNAECOLOGICAL TUMOURS. (1st September 2005) Authors: Vergote, I.; Amant, F.; Forget, F.; Canon, J. L.; Awada, A.; Dirix, L.; Van Belle, S. Journal: International journal of gynecological cancer Issue: Volume 15(2005)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms)⧉